3 results
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…
To compare health-related quality of life, specifically fatigue, in melanoma patients treated with immunotherapy who use or do not use a patient-centered mobile coaching and monitoring system (CAPABLE). We expect that by using the CAPABLE eHealth…
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.